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cluded older age, female gender, earlier year of entry, having 
spent 1 month or more in detention or prison, use of injected 
heroin and more years of intravenous use.  Conclusion: Our 
results highlight the fact that efforts to prevent and test for 
infections and to promote vaccination against HAV and HBV 
in heroin users need to be continued.  © 2015 S. Karger AG, Basel 
 Introduction 
 The history of heroin-assisted treatment (HAT) in 
Switzerland began more than 20 years ago. In 1994, HAT 
started in the context of a scientific project to assess the 
feasibility, impact on patients’ health and social function-
ing, safety, and societal impact (e.g. delinquency levels or 
incidence of starting heroin use) of heroin substitution 
for severely dependent heroin users. After years of politi-
cal discussions and uncertainty about the future of HAT, 
in 2008, the treatment received a definite legal basis 
through its integration into the Federal Law on Narcotics 
 [1] . The treatment is available for opioid users older than 
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 Abstract 
 Background/Aims: We report on the rates of hepatitis A vi-
rus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV) and 
human immunodeficiency virus (HIV) in 1,313 clients enter-
ing heroin-assisted treatment (HAT) in Switzerland from 
2003 to 2013. We identify predictors of HCV infection.  Meth-
ods: Data were collected using questionnaires within 
2 weeks of clients’ first entry into HAT. Prevalence of HAV, 
HBV, HCV and HIV was calculated using laboratory test re-
sults collected at entry or using reports of older test results. 
Predictors of HCV status were identified through multiple lo-
gistic regression analysis.  Results: Results show stable rates 
of HIV-positive clients and decreasing proportions of HAV- 
and HBV-infected clients. In 2013, there were 12% (n = 8) HIV-
, 20% (n = 12) HAV-, 20% (n = 12) HBV- and 52% HCV- (n = 34) 
positive clients. Vaccination against HAV and HBV had be-
come more frequent. Predictors of positive HCV status in-
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18 years, who have been opioid dependent for at least 
2 years, who have failed at least 2 treatment attempts for 
their opiate addiction, and who suffer medical, psycho-
logical or social deficits related to their drug use. Special-
ised treatment centres, of which there were 23 in 2003 and 
22 in 2013 (including 2 prisons), hold a permit to provide 
HAT.
 Behaviour associated with heroin provision and con-
sumption place users at increased risk of contracting in-
fections, including blood borne human immunodeficien-
cy virus (HIV), hepatitis B virus (HBV) and hepatitis C 
virus (HCV), and food or water-borne hepatitis A virus 
(HAV). These risks mainly arise when intravenous drug 
users share needles or drug preparation equipment or 
have unprotected sexual contacts, together with the struc-
tural conditions associated with inadequate hygiene, such 
as living in unstable housing and lacking or rejecting ac-
cess to healthcare for fear of arrest or discrimination  [2] .
 In the general Swiss population, HAV incidence be-
tween 2005 and 2013 decreased from 1.9 to 0.7 and HBV 
incidence from 1.2 to 0.8 per 100,000 inhabitants  [3] . 
Chronic hepatitis B prevalence (HBs antigen positivity) 
in Switzerland is estimated to be 0.3%. The prevalence of 
HCV antibody is currently estimated to be 0.7–1.0% of 
the general population; incidence decreased between 
2005 and 2013 from 1.0 to 0.6 per 100,000 inhabitants. 
Prevalence of HIV in Switzerland is estimated to be 0.3% 
 [4] . The last study reporting hepatitis and HIV prevalence 
in HAT clients in Switzerland used data from 2000 to 
2002  [5] . That study reported 41.2% HAV-, 53.3% HBV- , 
78.3% HCV- and 12.6% HIV-positive patients, which 
represented a reduction in HAV and HBV, but not in 
HCV and HIV infections, compared to two earlier HAT 
cohorts (1994–1996 and 1998). The authors concluded 
that HCV prevention, in particular, needed to be im-
proved and more consistent vaccination against HBV and 
HAV was required in intravenous drug users.
 The Swiss Federal Office for Public Health regards 
injecting drug users (IDUs) as a target group for com-
bined vaccination against HAV and HBV  [6] . There is 
currently no vaccine for HCV. In 70–85% of infected 
individuals, the disease becomes chronic and up to 1 
quarter of untreated patients suffer liver failure or liver 
cancer. Interferon-based treatments allow recovery in 
70–80% of patients. These treatments, however, are un-
popular, due to their high intensity and side effects. New 
interferon-free treatments for HCV (Sofosbuvir plus 
Ribavirin for 24 weeks in genotype 3) may be more tol-
erable for patients; however, with costs of up to 120,000 
Swiss Francs, these treatments are highly expensive  [7] . 
Thus, prevention of HCV continues to be the most im-
portant factor in tackling the disease. To optimise pre-
vention, risk factors for HCV seroconversion need to be 
identified. According to the literature, factors repeated-
ly associated with positive HCV or HCV antibody status 
in drug users included longer duration of intravenous 
drug use  [8–11] , female gender  [12, 13] , older age  [8, 14] , 
foreign ethnicity  [9, 11] and history of imprisonment  [9, 
11, 14] . These studies used data collected until 2007 and, 
except for one study  [10] , they investigated intravenous 
drug users, as opposed to users of other routes of admin-
istration. From a preventive point of view, it would be of 
interest to look at more recent data and to investigate 
HCV risk in users with other routes of drug administra-
tion.
 This study aims at reporting the development of HIV 
and hepatitis prevalence in HAT clients who were regis-
tered for treatment between 2003 and 2013. Therefore, 
this study is a continuation of the study of Gerlich et al. 
 [5] who used corresponding data from 1994 to 2002. Fur-
thermore, as HCV still appears to be the most widespread 
infection in drug users, together with the absence of vac-
cination against HCV and its high chronicity and hazard-
ous effects on the liver, the study aims at identifying so-
ciodemographic and drug use characteristics that predict 
HCV status in this sample of severely heroin-dependent 
individuals. Identifying these factors will help arrive at 
conclusions as to where the focus of HCV prevention 
should lie.
 Methods 
 Data Collection 
 Data were collected in the context of the Swiss monitoring sys-
tem of HAT established in 2000  [15] . Within this monitoring sys-
tem, entry questionnaires are collected in all Swiss HAT treatment 
centres within 2 weeks of entry into HAT. Data are collected by 
caregivers, usually physicians or social workers, in the form of an 
interview with the client and are subsequently submitted to the 
Swiss Research Institute for Public Health and Addiction. The en-
try questionnaire underwent 2 revisions at the end of 2004 and 
2012. For this study, full sociodemographic data were available for 
clients entering from 2005. For clients entering in 2003 and 2004, 
information is available on date of entry, treatment centre, age, 
gender, route of prescribed heroin administration, and HIV and 
hepatitis status.
 Measures 
 HIV and Hepatitis Status 
 For HIV and HAV, the date of the latest test and its result (‘neg-
ative’ or ‘positive’) were assessed. For HBV and HCV, the results 
of tests conducted at entry were assessed as follows: for HBV, re-
sponse options included ‘anti-HBc positive’, ‘anti-HBc negative’, 
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‘anti-HBs positive’, ‘anti-HBs negative’ and ‘not tested’ and for 
HCV, ‘anti-HCV positive’, ‘anti-HCV negative’, ‘HCV-PCR posi-
tive’, ‘HCV-PCR negative’ and ‘not tested’.
 Furthermore, information about vaccination against HAV and 
HBV was assessed using the question ‘Has a decision been made 
at entry to vaccinate against HAV/HBV?’. Response options were 
‘Yes’, ‘No, client is already vaccinated’, ‘No, vaccination not indi-
cated as client is seropositive’, ‘No, client rejects vaccination’ and 
‘No, due to another medical contraindication’.
 Predictors of HCV Status 
 Based on literature and clinical judgment, we considered the 
following variables as potential predictors of HCV status: gender, 
age at entry, nationality (Swiss vs. foreign), highest completed ed-
ucation (no or partly completed compulsory education, compul-
sory education, vocational education or apprenticeship or gen-
eral education, higher vocational education or university, other), 
marital status (unmarried, married, separated or divorced or wid-
owed), children (yes, no), housing in the 30 days prior to entry 
(stable, i.e. own or rented flat or house; unstable, i.e. hopping, 
shelter, hotel, homeless; institution, i.e. prison, hospital, therapeu-
tic institution), main source of income in the 30 days prior to en-
try (employment, pension, social welfare, partner or family or 
friends, drug dealing or illegal activities or prostitution, other), 
judicial decision as basis of HAT (yes, no), time spent in detention 
or prison (<1,  ≥ 1 month), 30-day point prevalence of heroin use 
prior to entry (0, 1–10, 11–20, 21–30 days), predominant form of 
heroin use (oral including smoke, nasal, injected, injected plus 
another form, not injected but several other forms), years of in-
travenous use, age at first heroin use and years of regular use (de-
fined as using heroin at least 3 times per week or on 2 consecutive 
days or more per week). Furthermore, we included a variable 
called ‘entry year group’, which split the cases into entries during 
2005–2008 and entries during 2009–2013. This split was based on 
a national HCV campaign starting in June 2008 and lasting sev-
eral years that aimed at enabling drug treatment centres to con-
duct their own campaigns by providing them with guidelines for 
giving advice, as well as supplying them with the necessary mate-
rials (flyers, films, hygiene articles, labelled syringes). This cam-
paign was supported by the Swiss Federal Office of Public Health 
 [16] .
 Statistical Methods 
 Missing Case Analysis 
 Missing case analyses were performed for clients entering HAT 
between 2005 and 2013. To examine differences between clients 
with and without a completed entry questionnaire, we conducted 
χ 2 tests for gender, treatment centre and year of entry, and t tests 
for age at entry. To examine differences between clients with and 
without information on HAV, HBV, HCV and HIV status, we 
conducted χ 2 tests for gender, treatment centre, year of entry, na-
tionality (Swiss vs. foreign), and t tests for age at entry and 30-day 
point prevalence of heroin use before entry.
 Calculation of Prevalence of HIV and Hepatitis 
 For HIV prevalence, the result of the latest test was used. For 
HAV, clients were categorised as ‘negative susceptible’ if test re-
sults were negative and/or the question on vaccination status did 
not indicate vaccination or seropositivity. If the response option 
‘No, client is already vaccinated’ was crossed, the client was catego-
rised as ‘vaccinated’. If the response option ‘No, vaccination not 
indicated as client is seropositive’ was crossed, the client was cat-
egorised as ‘gone through’. Clients with a positive test result and 
missing information on vaccination were categorised as ‘positive 
unknown’. We used old test results to assign an HAV status to cli-
ents whose test results at entry or information about vaccination 
were not available.
 With HBV, clients were categorised as ‘negative susceptible’ if 
anti-HBc or an old test result had been negative and no vaccination 
had taken place. If both anti-HBc and anti-HBs were positive, or if 
an old result had been positive and no test results at entry were 
available, clients were labelled as ‘gone through’. Clients were clas-
sified as ‘vaccinated’ if the response option ‘No, client is already 
vaccinated’ was crossed. If anti-HBc were positive and no anti-HBs 
results were reported, or if test results at entry were missing but 
‘vaccination not indicated as client is seropositive’ was crossed, the 
client was classified as ‘seropositive’.
 With HCV, if a negative anti-HCV result was available, the cli-
ents were classified as ‘negative’. If anti-HCV were positive but 
HCV-PCR were negative, the client was categorised as ‘gone 
through’. If anti-HCV and HCV-PCR were positive, the client was 
classified as ‘confirmed chronic’. If anti-HCV were positive but no 
HCV-PCR result was reported, the client was assigned the status 
‘seropositive’. If an old, positive anti-HCV test result, but no new-
er result was available, the status ‘old positive result’ was assigned. 
Although for HCV chronic disease is more probable than acute 
disease, we did not want to make any assumptions, as there is still 
a ca. 20% likelihood that the infection does not become chronic 
 [16] .
 To illustrate the source of decisive information on HIV or hep-
atitis status, we created a variable with the categories ‘old test re-
sult’, ‘new test result’, and additionally for HAV and HBV, ‘vac-
cination status question’. Furthermore, for old test results, we cal-
culated the interval (in years) between the test and entry into HAT.
 Predictor Analysis 
 Prior to predictor analysis, we imputed missing data on predic-
tor variables through multiple imputation using the multiple im-
putation procedure in SPSS 22.0. Based on the assumption that 
data were missing at random, all available sociodemographic and 
heroin use variables (n = 18) were used as predictors of imputed 
values. We imputed 15 datasets. Our reported results are based on 
the combined results from these datasets. The dependent variable 
‘HCV status’ was dichotomised into ‘negative’ or ‘ever positive’, 
the latter subsuming the categories ‘gone through’, ‘seropositive’, 
‘confirmed chronic’ and ‘old positive result’. Thus, the dependent 
variable ‘HCV status’ refers to HCV antibody tests regardless of 
any HCV-PCR tests.
 We identified predictors of HCV status using logistic regres-
sion analysis. To choose predictors for the initial model, we ap-
plied a mix of purposeful selection and selection based on statis-
tical significance (p  ≤ 0.25)  [17] . After testing the predictors by 
univariate analysis, we fitted the full model and excluded predic-
tors with p  > 0.05 stepwise, examining changes in beta coeffi-
cients of the remaining variables to detect potential multi-collin-
earity. In the next step, we added each previously excluded pre-
dictor again to examine its significance in the presence of the 
retained variables. We assessed the goodness of fit of the final 
main effects model in terms of variance explained (Nagelkerke’s 
R 2 ).
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 Results 
 Study Population 
 The sample consisted of 1,518 heroin users who en-
tered HAT for the first time between January 6, 2003 and 
November 19, 2013. Of these, only 13.6% (n = 205) pro-
vided a minimum of information as required by the ad-
ministrative entry procedure, instead of a fully completed 
entry questionnaire. There was no relationship between 
gender and form of prescribed heroin use and provision 
of a completed entry questionnaire (p > 0.05). Nor was 
there a difference in age at entry between clients who pro-
vided a questionnaire and those who did not (p > 0.05). 
There was, however, a significant association between 
year of entry (p < 0.01) as well as treatment centre (p < 
0.01) and providing a completed entry questionnaire. 
Rates of questionnaire completion varied between a min-
imum of 69.6% (n = 94) of all clients entering in 2007 and 
a maximum of 99.2% (n = 130) of all clients entering in 
2010 (mean 88.8%, SD 8.4%). With respect to treatment 
centres, questionnaire completion varied between 53.8% 
(n  = 7) of all clients entering one treatment centre be-
tween 2003 and 2013 and 97.1% (n = 33 and n = 34, re-
spectively) of all clients entering another treatment centre 
(mean 88.0%, SD 10.8%).
 Entry data were available for 1,313 clients (i.e. for 303 
entries from 2003 to 2004: gender, age, form of prescribed 
heroin use and HIV/hepatitis status; for 1,010 entries 
from 2005 to 2013: all variables). Clients had a mean age 
of 35.4 (SD 7.8, minimum  = 18, maximum  = 60) and 
21.7% (n  = 285) were female. As comparison, between 
2000 and 2002, clients had a mean age of 33.7 and there 
were 17.6% women  [5] . With respect to the form of pre-
scribed heroin use, 53.1% (n = 697) of clients were pre-
scribed intravenous heroin, 28.2% (n = 370) oral heroin, 
3.1% (n = 41) intramuscular heroin, 4.3% (n = 57) intra-
venous and oral, 4.6% (n = 60) intravenous and intramus-
cular, 0.2% (n = 3) oral and intramuscular heroin, and 
0.8% (n = 11) all 3 forms of heroin.
 There were 83.9% (n = 834) Swiss nationals. With re-
spect to the highest level of education, 8.1% (n = 81) had 
no or partly completed compulsory education, 29.7% 
(n = 296) had completed compulsory education (9 years 
of schooling), 56.0% (n = 557) had completed vocational 
education, apprenticeship or high school and 6.1% (n = 
61) had completed higher vocational education or uni-
versity. Almost three quarters of clients were unmarried 
(73.1%, n = 735), 8.5% (n = 86) were married and 18.4% 
(n = 185) were separated, divorced or widowed. Nearly 
three out of 10 clients had their own or adopted children 
(28.7%, n = 287). Few clients were in HAT on the basis of 
a judicial decision (5.6%, n = 55); however, 61.9% (n = 
538) had spent 1 month or longer in detention or prison. 
In the 30 days prior to entry, 69.3% (n = 695) had lived in 
stable housing, 12.8% (n = 128) in unstable housing and 
17.9% (n = 180) in an institution. Social welfare was the 
main source of income of 51.8% (n = 512) of clients, while 
22.3% (n = 220) survived on their pension or disability 
insurance, 12.4% (n = 123) on employment, between 2.2 
and 2.9% (n = 22–29) on unemployment insurance, on 
relatives or friends, on drug dealing or prostitution, or on 
various other sources of income.
 In the 30 days prior to entry, 17.8% (n = 174) had not 
used any illegal heroin, 18.4% (n = 180) had used illegal 
heroin on 1–10 days, 11.8% (n = 116) on 11–20 days and 
52.0% (n = 510) on more than 20 days. Most clients com-
bined injecting illegal heroin with another form of use 
(36.8%, n  = 334), while 34.7% (n  = 315) only injected, 
7.3% (n  = 66) used oral heroin (including smoking), 
14.1% (n = 128) nasal heroin and 7.2% (n = 65) combined 
several other forms of use without injecting. On average, 
clients had used heroin for the first time when aged 19.0 
(SD 5.4), which is in agreement with the findings of 
Gerlich et al.  [5] . Clients had used heroin regularly for 
13.4 years (SD 7.3; Gerlich et al.  [5] 11.6 years) and had 
used intravenous heroin for 9.7 years (SD 8.2).
 Prevalence of HIV and Hepatitis 
 Information on HIV status was available for 78.1% 
(n = 1,025), on HAV for 66.4% (n = 871), on HBV for 
70.4% (n = 924) and on HCV for 71.3% (n = 936) of the 
1,313 clients entering between 2003 and 2013 who pro-
vided a completed entry questionnaire.
 For HIV, in 48.3% (n = 495) of clients the information 
about status originated from test results at entry, while for 
51.7% (n = 530) of clients an old test result was available. 
Of the clients with old test results, 71.1% (n = 229) pro-
vided a result that was up to 2 years old. The decisive sta-
tus information for HAV was provided by the old test 
result in 25.0% (n = 218), by the new test result in 26.5% 
(n = 231) and by the question on vaccination status in 
48.5% (n = 422) of cases. Old HAV test results were no 
older than 2 years in 62.9% (n = 66) of cases. The decisive 
status information for HBV was provided by the old test 
result in 28.4% (n = 262), by the new test result in 30.2% 
(n = 279) and by the question on vaccination status for 
41.5% (n = 383) of clients. In 60.2% (n = 106) of clients 
with an old test result, this result was no older than 
2  years.  The decisive status information for HCV was 
provided by the old test result in 53.3% (n = 499) and by 
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the new test result in 46.7% (n = 437) of clients. Old test 
results were no older than 2 years in 63.7% (n = 181) of 
clients.
 There were no differences in gender and nationality 
(Swiss vs. non-Swiss) between clients with sufficient in-
formation on HIV and all hepatitis types and those with-
out sufficient information (all p > 0.05). Similarly, there 
were no age differences (p > 0.05). However, there was an 
association between the predominant form of heroin use 
and the method of providing sufficient information on 
HIV, HAV and HCV (all p < 0.05). Clients with sufficient 
information more frequently injected heroin than using 
other forms of administration. For example, 74.4% (n = 
503) of clients with sufficient information on HCV in-
jected heroin, vs. 62.8% (n = 145) of clients with insuffi-
cient information. Furthermore, clients with a lower 30-
day point prevalence of heroin use prior to entry were 
more likely to provide information on HIV and all hepa-
titis types than clients with a higher prevalence. For ex-
ample, 49.0% (n = 353) of clients with sufficient informa-
tion on HCV used heroin on more than 20 days, while this 
proportion was 60.6% (n = 154) in clients with insuffi-
cient information (p < 0.01).
 The results on prevalence of HIV and HAV, HBV and 
HCV are presented in  table 1 and  figures 1 – 4 . The preva-
lence of HIV-positive clients fluctuated around 10%, with 
the lowest percentage in 2008 (3.4%, n = 3) and the high-
est in 2006 (12.5%, n = 12). The proportion of HAV ever-
positive clients (i.e. lifetime prevalence) decreased from 
44.3% (n = 39) in 2003 to 18.7% (n = 14) in 2010. Since 
then, the proportion has seemed to fluctuate around 20%, 
apart from a deviation in 2011. The decrease in HAV life-
time prevalence coincides with an increasing number of 
vaccinated clients, from just over 20% to more than 30% 
in recent years. HBV lifetime prevalence was 48.9% (n = 
45) in 2003 and then underwent an unsteady decrease, to 
arrive at 20.0% in 2012 and 2013 (n = 15 and n = 12, re-
spectively). While in earlier years, one fifth to 1 quarter of 
clients were vaccinated against HBV, since 2010, at least 
one third of clients have been vaccinated. While HCV 
lifetime prevalence was 70.8% (n = 75) in 2003, this pro-
portion decreased to 54.0% in 2008, but has since fluctu-
ated around this level. On the basis of all positive new 
results, we calculated the lowest proportion of chronic 
courses of disease for 2010 (4.4%, n = 4) and the highest 
proportion for 2005 (9.4%, n = 9).
 Predictors of HCV 
 Univariate Analysis 
 Based on univariate analysis, the following character-
istics were positively associated with ever having been 
HCV positive: higher age at entry, being separated, di-
vorced or widowed, drug dealing, illegal activities or 
prostitution as main source of income, number of 
months spent in detention or prison, nasal, injected and 
injected plus another form of predominant heroin use, 
Table 1. Prevalence of HIV, HAV, HBV and HCV according to year of entry
HIV 2003–2004 2005–2007 2008–2010  2011–2013
n % n % n % n %
Positive 23 10.7 31 11.4 20 7.3 22 8.4
HAV
Vaccinated 38 21.3 64 26.8 75 31.5 73 33.8
Gone through 65 36.5 80 33.5 46 19.3 43 19.9
Seropositive 9 5.1 6 2.5 11 4.6 6 2.8
Ever positive (lifetime) 74 41.6 86 36.0 57 23.9 49 22.7
HBV
Vaccinated 46 23.8 60 23.3 76 30.3 76 34.2
Gone through 63 32.6 81 31.4 46 18.3 29 13.1
Seropositive 21 10.9 18 7.0 19 7.6 11 5.0
Ever positive (lifetime) 84 39.6 99 38.4 65 25.9 40 18.1
HCV
Gone through 3 1.4 12 4.9 11 4.5 9 3.8
Seropositive 41 19.8 47 19.1 39 15.8 33 14.0
Confirmed chronic 10 4.8 21 8.5 14 5.7 17 7.2
Old positive result 89 43.0 85 34.6 71 28.7 67 28.4
Ever positive (lifetime) 143 69.0 165 67.1 135 54.7 126 53.4
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number of years of regular use, years of intravenous drug 
use and having spent 1 month or more in detention or 
prison ( table 2 ). Meanwhile, entry year group and age at 
first heroin use were negative predictors of positive HCV 
status.
 Multivariate Model 
 According to Nagelkerke’s R 2 , the final model ex-
plained 22.5% of variance in HCV status. Multivariate 
predictors of HCV status included higher age at entry, 
female gender, entering between 2005 and 2008, having 
0
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 Fig. 1. Percentage of HIV-positive clients 
according to year of entry. 
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 Fig. 2. HAV status according to year of 
 entry. 
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 Fig. 3. HBV status according to year of en-
try. 
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spent 1 month or more in detention or prison, using in-
jected heroin, more years of intravenous use and lower 
age at first heroin use (table 3).
 Discussion 
 Our results show that decreasing proportions of HAV- 
and HBV-infected clients entered HAT in Switzerland 
between 2003 and 2013 (minus ca. 25% points). At the 
same time, vaccinations against HAV and HBV have be-
come more prevalent (plus ca. 11% points). Our findings 
indicate a continuation in the decrease in HAV and HBV 
infections as reported by Gerlich et al.  [5] . In addition, we 
observed a remarkable decrease in HCV-positive clients 
between 2003 and 2013 (minus 19.3% points). Thus, our 
overall results are highly encouraging in the context of the 
promotion of HAV and HBV vaccine and the prevention 
of HAV, HBV and HCV. HIV infections in new HAT en-
tries, in contrast, have remained stable throughout our 
studied period.
 Our observed prevalence of all infections, however, is 
still remarkably higher than their prevalence in the gen-
eral Swiss population  [3, 18] and in patients admitted to 
the emergency room of a Swiss university hospital (6.7% 
HBV and 2.7% HCV, respectively)  [19] . These contrasts 
highlight the fact that efforts to test and prevent infection 
and to promote vaccination against HAV and HBV in 
heroin users need to be continued.
 For the period of 2005–2008, the prevalence of HBV in 
our HAT sample was similar to that in IDUs in other 
 European countries (Europe: 39%; Swiss HAT: 34%)  [20] . 
According to our results, HCV remains the most frequent 
infection in HAT clients. A Spanish HAT study reported 
an even higher prevalence (94%) than that found in our 
study (69%) in participants recruited 2003–2004  [21] . 
The prevalence of HCV found in our sample between 
2005 and 2009 (61%) however, is similar to the prevalence 
reported in Canadian HAT clients (63%)  [22] and gener-
ally in IDUs in Europe (58%)  [20] . We were not able to 
identify more recent international reports on the preva-
lence of any hepatitis type in HAT clients or more gener-
ally, in IDUs. Regarding HIV, the Spanish HAT study 
found a higher rate (40.3%) of affected clients recruited 
in 2003–2004. Prevalence reported in Canadian HAT cli-
ents (10%) recruited from 2005 to 2008 is in line with our 
prevalence. Our finding that HIV prevalence has re-
mained stable is in line with IDU data from most coun-
tries in the European Union/European Economic Area in 
the period from 2008 to 2011  [23] .
 We found relative decreases of 54.5 and 40.2% in cli-
ents classified as having gone through HAV and HBV 
between the periods of 2003–2004 and 2011–2013. 
However, we cannot say whether some of the cases clas-
sified as ‘HBV gone through’ might have developed 
chronic infection, as the questionnaire did not assess 
eventual HBs antigens. In drug consumers, up to 40% 
of  individuals with only HBc antibody detectable 
(HBc alone) might have low levels of circulating HBV 
DNA  (http://www.viralhepatitis.ch/de/node/691 [in 
 German]). Chronic courses can affect up to 85% of 
HCV-positive individuals, so that the rate of chronic 
courses that we found (maximally 37.5% in 2007) is very 
low. As many HCV-PCR results were missing, we were 
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 Fig. 4. HCV status according to year of en-
try. 
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unable to classify more clients as ‘HCV chronic’. We 
suspect that missing data can be partly explained by in-
sufficient knowledge about adequate HCV testing 
among health care providers.
 According to our results, clients of HAT with more 
years of intravenous drug use were more likely to be HCV 
positive than clients with a shorter experience of intrave-
nous use. This finding is in line with numerous other 
findings  [8–11] . It illustrates that longer drug use implies 
more cumulative risk exposure. As with the duration of 
intravenous use, greater age at entry and lower age at first 
heroin use predicted HCV-positive status. Both of these 
variables are likely to coincide with longer drug intake.
 Use of injected rather than oral heroin was linked to 
an increase in the risk of being HCV-positive by up to 3.4-
fold. Although oral (and nasal) drug use has also been as-
sociated with a substantial risk of HCV  [24] , in our sam-
ple, only 3% of clients with oral use (or 12% for nasal use) 
were HCV-positive, compared to ca. 40% in clients with 
intravenous use. Thus, in our sample of HAT clients, in-
travenous use implied a clearly higher risk of HCV expo-
sure. The importance of targeting users before they start 
intravenous use, a period that may last up to 2 years, has 
been emphasised. During this period, efforts should aim 
at preventing intravenous use, by raising users’ awareness 
of the advantages of non-parenteral routes of administra-
tion  [10] . Frequency of heroin use, however, did not affect 
the HCV status. In fact, descriptive data showed that 
HCV risk decreased as the frequency of days of using her-
oin prior to HAT entry increased. This is at first sight a 
curious finding, but it has also been found in another 
study  [25] . We suggest that individuals with higher fre-
quency of use are more likely to experience complications 
that lead them to medical centres where they are also con-
fronted with HCV prevention.
 Individuals who entered HAT in the period from 2005 
to 2008 were more likely to be HCV-positive than indi-
viduals who entered more recently. This might be due to 
the positive effect of the Swiss-wide HCV campaign im-
plemented in 2008  [16] .
 Entering HAT on the basis of a judicial decision was 
not associated with HCV status. In contrast, having spent 
time in prison predicted HCV status. This is in line with 
numerous earlier findings  [9, 11, 25] . In Switzerland, the 
precise extent of drug use in prisons is unknown and po-
litical neglect of this problem has been criticised. Up to 
one quarter of prisoners are drug dependent and it is sus-
pected that drugs are regularly smuggled or sent to pris-
oners  [26] . To prevent transmission of HCV in prisons, 
needle and syringe exchange or substitution programs in 
all prisons should be considered  [25] . Aside from infec-
tion with HCV during imprisonment, for some individu-
als, the time in prison may be the end point of a history 
of marginalisation, involving not only criminal activity, 
but also unemployment, difficulties in finding accommo-
dation or similar conditions that are associated with risk 
behaviours, reduced access to prevention and medical 
care, and therefore higher HCV risk  [11] . Living in un-
stable housing or having illegal activities or prostitution 
as the main source of income could be considered other 
indicators of marginalisation, but these factors do not 
predict the HCV status. This could be because the time 
window of these assessments (30 days prior to entry) was 
not representative enough of clients’ long-term situation.
 Finally, according to our findings, female HAT clients 
had a higher risk of being HCV-positive than male clients. 
Table 3.  Multivariate predictors of HCV status
B SE p OR 95% CI
Age at entry 0.05 0.01 0.00 1.05 1.02–1.08
Female gender 0.62 0.22 0.01 1.85 1.21–2.83
Entering after 2008 –0.45 0.17 0.01 0.64 0.46–0.89
Having spent 1 month or more in detention or prison 0.68 0.19 0.00 1.97 1.36–2.83
Form of heroin use 
Oral including smoking (ref.)
Nasal 0.61 0.42 0.15 1.85 0.81–4.20
Injected 1.17 0.39 0.00 3.24 1.50–6.70
Injected plus other form 1.23 0.39 0.00 3.42 1.60–7.27
Not injected but several other forms 0.11 0.49 0.83 1.12 0.42–2.94
Years of intravenous use 0.04 0.01 0.00 1.04 1.02–1.07
Age at first heroin use –0.04 0.02 0.03 0.96 0.92–1.00
Constant –2.23 0.57 0.00 0.11 0.04–0.33
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This finding is consistent with previous studies  [12, 13] . 
One explanation might be that females are biologically 
more susceptible to contract HCV  [12] . Furthermore, be-
havioural differences could play a role. For instance, 
women were more likely to have ever sold sex than men 
 [27] . Other studies found that women were more likely to 
engage in equipment sharing than men, and that women 
tended to be receptive in sharing syringes more often than 
men  [28] . Similarly, it could be assumed that women tend 
to have older sexual or injecting partners with longer drug 
careers and thus with a higher risk of HCV, thereby en-
hancing women’s risk of infection. In addition, female 
substance abusers were more likely to have a history of 
overdose, psychiatric illness, and alcohol intake above the 
national recommended guidelines, all of which might fa-
cilitate high-risk behaviour  [29] . Our analysis is unaffect-
ed by the finding that women are more likely to clear HCV 
than men  [30] because in our dependent variable, we 
summarised individuals with current or past infection.
 Nationality was not significantly associated with HCV 
risk in multivariate analysis. This finding disagrees with 
other findings regarding different ethnicities  [9, 11] . It 
suggests that in Switzerland, foreign nationality is not a 
factor in explaining differences in drug users’ HCV risk 
exposure or access to prevention. Marital status or having 
children did not predict HCV status either. This contrasts 
with another study that identified ‘being divorced’ and 
‘parenthood’ as risk factors of HCV, which has been ex-
plained by the fact that divorced individuals and those 
who have children are usually older, and older age is a risk 
factor in itself  [8] .
 One limitation of our study is that we were not able to 
directly supervise the process of information collection. 
This has potential implications for data quality, particu-
larly in the case of the relatively complex assessment of 
hepatitis status. Our data were collected by the institu-
tions and then passed on to us. For laboratory results tak-
en at entry into HAT, we must trust that blood tests were 
conducted using scientifically appropriate methods and 
that results were correctly reported to and by the care-
giver filling in the questionnaire. Older test results would 
either rely on clients’ self-reports, which might be suscep-
tible to recall bias, or caregivers’ investigations with rel-
evant information sources. Thus, the results may be im-
precise, particularly the older results.
 Furthermore, even though sharing equipment is con-
sidered to be the most evident route of infection transmis-
sion in IDUs, our multivariate analysis is missing this po-
tentially important predictor. The format used to assess 
this variable in our questionnaire would have substan-
tially reduced the number of cases for the logistic regres-
sion analysis, as only those with intravenous use in the 
previous 6 months were asked about sharing equipment. 
Despite strong evidence for equipment sharing as a factor 
of HCV, other studies have failed to show such an asso-
ciation in multivariate analyses  [9, 10] . This could be be-
cause the assessment missed equipment other than nee-
dles or syringes or because of methodological bias, such 
as referring the assessment of equipment sharing to a 
short time window  [9] .
 Another limitation concerns the differing number of 
completed questionnaires per year. In 2007, only 70% of 
questionnaires were completed. Thus, for 2007, data are 
less representative than for other years and the absolute 
prevalence of hepatitis and HIV for that year should be 
interpreted more cautiously. Nevertheless, over a period 
of 10 years, we observed clear developments in the preva-
lence of hepatitis and HIV that match the findings of 
Gerlich et al. [5] for the years before our study. These ob-
servations indicate the validity of our data. An associated 
limitation is that some treatment centres provided more 
data than others. The institution with the lowest rate of 
completed questionnaires (54%) was very small, with 
only 13 new entries in 10 years. Therefore, a potential se-
lection bias in this institution carries little weight in our 
analysis. The institutions with the next lowest completion 
rates provided 67% (n = 73) and 76% (n = 31) of question-
naires. Thus, across treatment centres there was little 
variation in completion rates.
 Clients with a lower rate of heroin use and those who 
injected heroin were more likely to provide data on hepa-
titis and HIV status. While we cannot exclude a small bias 
towards less severe users and those using heroin intrave-
nously in our results on prevalence, this problem does not 
extend to multivariate analysis, in which both variables 
were accounted for as predictors.
 Conclusion 
 Our study presents recent data on hepatitis and HIV 
infection rates in HAT clients, a severely affected sub-
group of heroin users. Further, we report developments 
in hepatitis and HIV infection in these clients since 2003. 
We observed decreasing prevalence rates of HAV, HBV 
and HCV and simultaneous increases in vaccination rates 
against HAV and HBV in our sample of severely addicted 
heroin users. These developments are highly encouraging 
and reinforce further investment into preventive pro-
grams, such as the national hepatitis campaign, which 
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started in 2008 and is still ongoing. Hepatitis prevalence 
in HAT clients still lies at a higher level than in the gen-
eral population. Thus, efforts in the prevention and vac-
cination of heroin users should continue. HIV rates have 
remained stable during the observation period. As around 
10% of HAT clients were still HIV-positive in 2013, fur-
ther HIV prevention should take place in this population.
 Our predictor analysis showed that the focus of HCV 
prevention should be centered around two areas: first on 
the period before heroin users actually start injecting 
themselves with the drug and second on female heroin 
users. Furthermore, our results support political efforts to 
implement needle and syringe exchange programs in 
prisons. 
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